What is RISET ?

Reprogramming the Immune System for Establishment of Tolerance

Transplantation dramatically improves survival of patients with established organ failure.  

However, as a direct consequence of immunosuppressive drugs, recipients have a significantly  increased risk of both infections and malignancies. Recent scientific advances indicate that the induction of tolerance, defined as permanent acceptance of transplant in absence of continuous immunosuppression, is an achievable goal.

RISET is a multinational European project financed by the European Commission (10M Euros)within the Sixth Framework Programme, that will focus on the translation of these advances in research into clinical practice and industrial development.  The RISET project commenced in March 2005 and finished at the end of August 2010.  The Consortium comprised of 26 partners from all over Europe.  12 clinical studies have been undertaken, 6 of which were aimed at the minimization of immunosuppression - a move towards more personalised medicine in transplantation.  More than 100 scientists have been involved in the research as well as clinicians, project managers, statisticians, data managers, ethicists and finance officers.

 

The Project Mission 

 

 "Translating advances in transplantation research for the benefit of transplant  patients"

 

Project goals

 

  • The development of reliable tests to predict tolerance: identify transplant recipients who are truly tolerant or require minimal immunosuppression
  • To assess patients enrolled in RISET pilot clinical investigations to determine the clinical and immunological outcome
  • To stimulate debate about ethical aspects of tolerance induction protocols to develop appropriate guidelines
  • To establish educational programs on transplantation tolerance for the patients and their families, for physicians, scientists and nurses
  • To identify new genes and molecules relevant for diagnosis and the development of new therapies for tolerance induction in the future

 

Potential impact and benefits

 Potential impact 

  • Improving the health and quality of life of transplant recipients
  • Saving health-care costs related to transplantation
  • Creating a competitive and innovative European task force to translate transplantation tolerance into clinical practice
  • Building a new partnership between the academic and the private sector to promote industrial activities in the field of transplantation tolerance (TRIP)
  • Establishing novel training programmes for physicians and scientists
  • Involving stakeholders in the implementation of innovation therapies in transplantation
  • New and more effective ways to prevent organ rejection
  • Improved survival rates for organ recipients
  • Improvements in patient care
  • Extended life expectancy
  • Better quality of life

Benefits

  • Transplants will function for longer
  • Enabling personalised medicine for transplant recipients
  • Improvements in individual patient care and quality of life for transplant recipients
  • Saving healthcare costs related to transplantation
  • New and more effective ways to prevent organ rejection